Drug intelligence / Profile preview

LY3478006

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

LY3478006 is a small molecule drug that was developed by Eli Lilly and Company. It was investigated as a subcutaneously and intravenously administered agent, with its mechanism of action remaining undefined or unknown. The drug reached phase 1 clinical trials in healthy volunteers to evaluate its safety, tolerability, and pharmacokinetics but the development was subsequently discontinued. No specific therapeutic indication or disease target has been publicly disclosed for this compound.

Beyond the preview

Go deeper on LY3478006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3478006.

Explore the full profile